A Cognitive-Emotional Biomarker for Predicting Remission with Antidepressant Medications: A Report from the iSPOT-D Trial

Neuropsychopharmacology

Volumn 40, Issue 6, 2015, Pages 1332-1342

  Etkin, Amit ^a,b   Patenaude, Brian ^a,b   Song, Yun Ju C ^c   Usherwood, Timothy ^c   Rekshan, William ^d,e   Schatzberg, Alan F ^a   Rush, A John ^f   Williams, Leanne M ^a,b,c  

^a STANFORD UNIVERSITY   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF SYDNEY   (Australia)

^d Brain Resource Ltd   (Australia)

^e Brain Resource International Database   (United States)

^f NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CITALOPRAM; DELAYED RELEASE FORMULATION; SERTRALINE; VENLAFAXINE;

ADOLESCENT; ADULT; AGED; CLINICAL TRIAL; COGNITION; COMPUTER; CONTROLLED STUDY; DELAYED RELEASE FORMULATION; DEPRESSIVE DISORDER, MAJOR; EMOTION; FEMALE; HUMAN; MALE; MIDDLE AGED; MULTICENTER STUDY; PROGNOSIS; PSYCHOLOGIC TEST; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIDEPRESSIVE AGENTS; CITALOPRAM; COGNITION; COMPUTERS; DELAYED-ACTION PREPARATIONS; DEPRESSIVE DISORDER, MAJOR; EMOTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PSYCHIATRIC STATUS RATING SCALES; PSYCHOLOGICAL TESTS; SERTRALINE; TREATMENT OUTCOME; VENLAFAXINE HYDROCHLORIDE; YOUNG ADULT;

EID: 84939989691     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2014.333     Document Type: Article

References (28)

1. th edn American Psychiatric Association: Washington, DC.
2. Dawes SE, Jeste DV, Palmer BW (2011). Cognitive profiles in persons with chronic schizophrenia. J Clin Exp Neuropsychol 33: 929-936.
3. Dunkin JJ, Leuchter AF, Cook IA, Kasl-Godley JE, Abrams M, Rosenberg-Thompson S (2000). Executive dysfunction predicts nonresponse to fluoxetine in major depression. J Affect Disord 60: 13-23.
4. Dunn OJ (1961). Multiple comparisons among means. J Am Stat Assoc 56 : 52-64.
5. Gorlyn M, Keilp JG, Grunebaum MF, Taylor BP, Oquendo MA, Bruder GE et al (2008). Neuropsychological characteristics as predictors of SSRI treatment response in depressed subjects. J Neural Transm 115: 1213-1219.
6. Gotlib IH, Joormann J (2010). Cognition and depression: current status and future directions. Annu Rev Clin Psychol 6: 285-312.
7. Hamilton M (1960). A rating scale for depression. J Neurol Neurosurg Psychiatry 23: 56-62.
8. nd edn Springer-Verlag: New York.
9. Horan WP, Goldstein G (2003). A retrospective study of premorbid ability and aging differences in cognitive clusters of schizophrenia. Psychiatry Res 118: 209-221.
10. Insel T, Cuthbert B, Garvey M, Heinssen R, Pine DS, Quinn K et al (2010). Research domain criteria (RDoC): toward a new classification framework for research on mental disorders. Am J Psychiatry 167: 748-751.
11. Kline RB (2013). Beyond Significance Testing: Statistics Reform in the Behavioral Sciences. American Psychological Association.
12. Leuchter AF, Morgan M, Cook IA, Dunkin J, Abrams M, Witte E (2004). Pretreatment neurophysiological and clinical characteristics of placebo responders in treatment trials for major depression. Psychopharmacology (Berl) 177: 15-22.
13. Mahalanobis PC (1936). On the generalized distance in statistics. Proc Natl Inst Sci India 2: 49-55.
14. Maroco J, Silva D, Rodrigues A, Guerreiro M, Santana I, de Mendonca A (2011). Data mining methods in the prediction of dementia: a real-data comparison of the accuracy, sensitivity and specificity of linear discriminant analysis, logistic regression, neural networks, support vector machines, classification trees and random forests. BMC Res Notes 4: 299.
15. Mathersul D, Palmer DM, Gur RC, Gur RE, Cooper N, Gordon E et al (2009). Explicit identification and implicit recognition of facial emotions: II. Core domains and relationships with general cognition. J Clin Exp Neuropsychol 31: 278-291.
16. Paul RH, Lawrence J, Williams LM, Richard CC, Cooper N, Gordon E (2005). Preliminary validity of "integneuro": a new computerized battery of neurocognitive tests. Int J Neurosci 115: 1549-1567.
17. Rush AJ, Trivedi MH, Ibrahim HM, Carmody TJ, Arnow B, Klein DN et al (2003). The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry 54: 573-583.
18. Rush AJ, Trivedi MH, Wisniewski SR, Stewart JW, Nierenberg AA, Thase ME et al Team SDS (2006). Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med 354: 1231-1242.
19. Saveanu R, Etkin A, Duchemin A-M, Gyurak A, DeBattista C, Schatzberg AF et al. The International Study to Predict Optimized Treatment for Depression (iSPOT-D): Outcomes from the acute phase of antidepressant treatment. J Psyc Res in press.
20. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E et al (1998). The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 59(Suppl 20): 22-33 quiz 34-57.
21. Snyder HR (2013). Major depressive disorder is associated with broad impairments on neuropsychological measures of executive function: a meta-analysis and review. Psychol Bull 139: 81-132.
22. Tatsumi M, Groshan K, Blakely RD, Richelson E (1997). Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol 340: 249-258.
23. Taylor BP, Bruder GE, Stewart JW, McGrath PJ, Halperin J, Ehrlichman H et al (2006). Psychomotor slowing as a predictor of fluoxetine nonresponse in depressed outpatients. Am J Psychiatry 163: 73-78.
24. Trivedi MH, Fava M, Wisniewski SR, Thase ME, Quitkin F, Warden D et al Team SDS (2006a). Medication augmentation after the failure of SSRIs for depression. N Engl J Med 354: 1243-1252.
25. Trivedi MH, Rush AJ,Wisniewski SR, Nierenberg AA,Warden D, Ritz L et al Team SDS (2006b). Evaluation of outcomes with citalopram for depression using measurement-based care in STAR∗D: implications for clinical practice. Am J Psychiatry 163: 28-40.
26. World Health Organization, Mental health: mental health atlas 2011. World Health Organization; Switzerland, 2012 (cited June 28, 2011) http://www.who.int/mental-health/publications/mental-health-atlas-2011/en/index.html.
27. Williams LM, Mathersul D, Palmer DM, Gur RC, Gur RE, Gordon E (2009). Explicit identification and implicit recognition of facial emotions: I. Age effects in males and females across 10 decades. J Clin Exp Neuropsychol 31: 257-277.
28. Williams LM, Rush AJ, Koslow SH, Wisniewski SR, Cooper NJ, Nemeroff CB et al (2011). International Study to Predict Optimized Treatment for Depression (iSPOT-D), a randomized clinical trial: rationale and protocol. Trials 12: 4.